Fact Sheet |
Invest in Biotech: Request Our Investor Package >> |
US Citizens
Please note that US shareholders can purchase BioMS shares through a registered broker and/or online trading service. Have more questions? Please email BioMS at info@biomsmedical.com or call toll-free 1-866-701-6033.
Click here to view the complete fact sheet PDF
Investing Facts
- Listed on the Toronto Stock Exchange (TSX): Stock Symbol "MS"
- Fiscal Year-End: December 31st
- Shares Outstanding: 91,163,323 (as of August 15, 2008)
- 52-week Range: $1.70-$4.39 (as of August 15, 2008)
- Working Capital: $93.1 million (as of June 30, 2008 and excludes US$10 million milestone payment from Lilly)
Investing Highlights
- Dirucotide (MBP8298) is the only novel agent for secondary progressive MS in phase III trials
- Dirucotide (MBP8298) represents a new class of drug with potential significant advantages
- Dirucotide (MBP8298) has blockbuster potential in a large underserved market
- Potential near-term value creating milestones
BioMS Medical Corporate Fact Sheet and Company Brochure:
|
|
|
Request an Investor Package >>